Alessandro Granito

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2699981/publications.pdf

Version: 2024-02-01

207 papers	10,523 citations	26567 56 h-index	34900 98 g-index
214 all docs	214 docs citations	214 times ranked	10797 citing authors

#	Article	IF	Citations
1	Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, The, 2017, 389, 56-66.	6.3	2,771
2	Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: A multicenter prospective study. Hepatology, 2016, 63, 827-838.	3.6	467
3	Field-practice study of sorafenib therapy for hepatocellular carcinoma: A prospective multicenter study in Italy. Hepatology, 2011, 54, 2055-2063.	3.6	321
4	Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial. Journal of Hepatology, 2018, 69, 353-358.	1.8	270
5	Antiendomysial and antihuman recombinant tissue transglutaminase antibodies in the diagnosis of coeliac disease. European Journal of Gastroenterology and Hepatology, 2005, 17, 85-91.	0.8	202
6	Contrast ultrasound LI-RADS LR-5 identifies hepatocellular carcinoma in cirrhosis in a multicenter restropective study of 1,006 nodules. Journal of Hepatology, 2018, 68, 485-492.	1.8	195
7	A multifaceted imbalance of T cells with regulatory function characterizes type 1 autoimmune hepatitis. Hepatology, 2010, 52, 999-1007.	3.6	175
8	Review article: autoimmune hepatitis - current management and challenges. Alimentary Pharmacology and Therapeutics, 2013, 38, 887-913.	1.9	146
9	High prevalence of celiac disease in Italian general population. Digestive Diseases and Sciences, 2001, 46, 1500-1505.	1.1	138
10	Celiac disease in autoimmune cholestatic liver disorders. American Journal of Gastroenterology, 2002, 97, 2609-2613.	0.2	136
11	Autoimmune hepatitis in Italy: The Bologna experience. Journal of Hepatology, 2009, 50, 1210-1218.	1.8	133
12	Non-transplant therapies for patients with hepatocellular carcinoma and Child-Pugh-Turcotte class B cirrhosis. Lancet Oncology, The, 2017, 18, e101-e112.	5.1	123
13	COVIDâ€19 and Immunological Dysregulation: Can Autoantibodies be Useful?. Clinical and Translational Science, 2021, 14, 502-508.	1.5	120
14	New hallmark of hepatocellular carcinoma, early hepatocellular carcinoma and high-grade dysplastic nodules on Gd-EOB-DTPA MRI in patients with cirrhosis: a new diagnostic algorithm. Gut, 2018, 67, 1674-1682.	6.1	114
15	The Serological Profile of the Autoimmune Hepatitis/Primary Biliary Cirrhosis Overlap Syndrome. American Journal of Gastroenterology, 2009, 104, 1420-1425.	0.2	111
16	VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: The ALICEâ€1 study. International Journal of Cancer, 2014, 135, 1247-1256.	2.3	109
17	Usefulness of Antibodies to Deamidated Gliadin Peptides in Celiac Disease Diagnosis and Follow-up. Digestive Diseases and Sciences, 2008, 53, 1582-1588.	1.1	107
18	Hepatocellular carcinoma in viral and autoimmune liver diseases: Role of CD4+ CD25+ Foxp3+ regulatory T cells in the immune microenvironment. World Journal of Gastroenterology, 2021, 27, 2994-3009.	1.4	103

#	Article	IF	Citations
19	Clinical Impact and Safety of Anticoagulants for Portal Vein Thrombosis in Cirrhosis. American Journal of Gastroenterology, 2019, 114, 258-266.	0.2	99
20	Deamidated Gliadin Peptide Antibodies as a Routine Test for Celiac Disease. Journal of Clinical Gastroenterology, 2010, 44, 186-190.	1.1	98
21	Impact of gadoxetic acid (Gdâ€<scp>EOB</scp>â€<scp>DTPA</scp>)â€enhanced magnetic resonance on the nonâ€invasive diagnosis of small hepatocellular carcinoma: a prospective study. Alimentary Pharmacology and Therapeutics, 2013, 37, 355-363.	1.9	98
22	Yttriumâ€90 radioembolization vs sorafenib for intermediateâ€locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis. Liver International, 2015, 35, 1036-1047.	1.9	94
23	Patterns of appearance and risk of misdiagnosis of intrahepatic cholangiocarcinoma in cirrhosis at contrast enhanced ultrasound. Liver International, 2013, 33, 771-779.	1.9	91
24	Portal vein thrombosis relevance on liver cirrhosis: Italian Venous Thrombotic Events Registry. Internal and Emergency Medicine, 2016, 11, 1059-1066.	1.0	90
25	Antibodies to filamentous actin (F-actin) in type 1 autoimmune hepatitis. Journal of Clinical Pathology, 2006, 59, 280-284.	1.0	83
26	Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma. Journal of Hepatology, 2017, 67, 65-71.	1.8	83
27	Platelet Count Does Not Predict Bleeding in Cirrhotic Patients: Results from the PRO-LIVER Study. American Journal of Gastroenterology, 2018, 113, 368-375.	0.2	82
28	'True' antimitochondrial antibody-negative primary biliary cirrhosis, low sensitivity of the routine assays, or both?. Clinical and Experimental Immunology, 2004, 135, 154-158.	1.1	79
29	Antibodies to SSâ€A/Roâ€52kD and centromere in autoimmune liver disease: a clue to diagnosis and prognosis of primary biliary cirrhosis. Alimentary Pharmacology and Therapeutics, 2007, 26, 831-838.	1.9	77
30	Natural Course of Chronic HCV and HBV Infection and Role of Alcohol in the General Population: The Dionysos Study. American Journal of Gastroenterology, 2008, 103, 2248-2253.	0.2	75
31	Antinuclear antibodies as ancillary markers in primary biliary cirrhosis. Expert Review of Molecular Diagnostics, 2012, 12, 65-74.	1.5	74
32	Experience with regorafenib in the treatment of hepatocellular carcinoma. Therapeutic Advances in Gastroenterology, 2021, 14, 175628482110169.	1.4	74
33	Antimitochondrial Antibodies and Other Antibodies in Primary Biliary Cirrhosis: Diagnostic and Prognostic Value. Clinics in Liver Disease, 2008, 12, 261-276.	1.0	72
34	Genetic distinctions between autoimmune hepatitis in Italy and North America. World Journal of Gastroenterology, 2005, 11, 1862.	1.4	70
35	Prognostic significance of adverse events in patients with hepatocellular carcinoma treated with sorafenib. Therapeutic Advances in Gastroenterology, 2016, 9, 240-249.	1.4	70
36	A metaâ€analysis of single <scp>HCV</scp>â€untreated arm of studies evaluating outcomes after curative treatments of <scp>HCV</scp>â€related hepatocellular carcinoma. Liver International, 2017, 37, 1157-1166.	1.9	70

#	Article	IF	Citations
37	Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of <scp>HCV</scp> eradication does not depend on the use of interferon. Alimentary Pharmacology and Therapeutics, 2017, 45, 160-168.	1.9	70
38	PML Nuclear Body Component Sp140 Is a Novel Autoantigen in Primary Biliary Cirrhosis. American Journal of Gastroenterology, 2010, 105, 125-131.	0.2	69
39	A Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis. British Journal of Cancer, 2013, 108, 21-24.	2.9	69
40	The changing scenario of hepatocellular carcinoma in Italy: an update. Liver International, 2021, 41, 585-597.	1.9	69
41	Characterization of Primary and Recurrent Nodules in Liver Cirrhosis Using Contrast-Enhanced Ultrasound: Which Vascular Criteria Should Be Adopted?. Ultraschall in Der Medizin, 2013, 34, 280-287.	0.8	67
42	The evolutionary scenario of hepatocellular carcinoma in Italy: an update. Liver International, 2017, 37, 259-270.	1.9	67
43	Coeliac Disease in Patients with Autoimmune Thyroiditis. Digestion, 2001, 64, 61-65.	1.2	66
44	Expert clinical management of autoimmune hepatitis in the real world. Alimentary Pharmacology and Therapeutics, 2017, 45, 723-732.	1.9	66
45	Antinuclear antibodies giving the 'multiple nuclear dots' or the 'rim-like/membranous' patterns: diagnostic accuracy for primary biliary cirrhosis. Alimentary Pharmacology and Therapeutics, 2006, 24, 1575-1583.	1.9	65
46	Clinical Findings and Anti-Neuronal Antibodies in Coeliac Disease with Neurological Disorders. Scandinavian Journal of Gastroenterology, 2002, 37, 1276-1281.	0.6	64
47	HCV and Autoimmunity. Current Pharmaceutical Design, 2008, 14, 1678-1685.	0.9	64
48	Management of adverse events with tailored sorafenib dosing prolongs survival of hepatocellular carcinoma patients. Journal of Hepatology, 2019, 71, 1175-1183.	1.8	64
49	Smooth Muscle Antibodies and Type 1 Autoimmune Hepatitis. Autoimmunity, 2002, 35, 497-500.	1.2	63
50	Metronomic capecitabine as second-line treatment in hepatocellular carcinoma after sorafenib failure. Digestive and Liver Disease, 2015, 47, 518-522.	0.4	63
51	Sera of Patients With Celiac Disease and Neurologic Disorders Evoke a Mitochondrial-Dependent Apoptosis In Vitro. Gastroenterology, 2007, 133, 195-206.	0.6	61
52	Clinical and economical impact of 2010 AASLD guidelines for the diagnosis of hepatocellular carcinoma. Journal of Hepatology, 2014, 60, 995-1001.	1.8	61
53	Clinical features of type 1 autoimmune hepatitis in elderly Italian patients. Alimentary Pharmacology and Therapeutics, 2005, 21, 1273-1277.	1.9	60
54	Anti-ganglioside antibodies in coeliac disease with neurological disorders. Digestive and Liver Disease, 2006, 38, 183-187.	0.4	60

#	Article	IF	Citations
55	Anti-actin IgA antibodies in severe coeliac disease. Clinical and Experimental Immunology, 2004, 137, 386-392.	1.1	58
56	Validation of simplified diagnostic criteria for autoimmune hepatitis in Italian patients. Hepatology, 2009, 49, 1782-1783.	3.6	58
57	The role of antitissue transglutaminase assay for the diagnosis and monitoring of coeliac disease: a French-Italian multicentre study. Journal of Clinical Pathology, 2003, 56, 389-393.	1.0	57
58	Clinical Impact of Non--Organ-Specific Autoantibodies on the Response to Combined Antiviral Treatment in Patients with Hepatitis C. Clinical Infectious Diseases, 2005, 40, 501-507.	2.9	57
59	Susceptibility to Thyroid Disorders in Hepatitis C. Clinical Gastroenterology and Hepatology, 2005, 3, 595-603.	2.4	57
60	Fatigue and pruritus at onset identify a more aggressive subset of primary biliary cirrhosis. Liver International, 2015, 35, 636-641.	1.9	57
61	Anti tissue transglutaminase antibodies as predictors of silent coeliac disease in patients with hypertransaminasaemia of unknown origin. Digestive and Liver Disease, 2001, 33, 420-425.	0.4	56
62	Current guidelines for the management of celiac disease: A systematic review with comparative analysis. World Journal of Gastroenterology, 2022, 28, 154-176.	1.4	56
63	Prevalence of silent coeliac disease in atopics. Digestive and Liver Disease, 2000, 32, 775-779.	0.4	53
64	Serum Albumin Is Inversely Associated With Portal Vein Thrombosis in Cirrhosis. Hepatology Communications, 2019, 3, 504-512.	2.0	53
65	Anti-Saccharomyces cerevisiae and perinuclear anti-neutrophil cytoplasmic antibodies in coeliac disease before and after gluten-free diet. Alimentary Pharmacology and Therapeutics, 2005, 21, 881-887.	1.9	51
66	Increased risk of nonalcoholic fatty liver disease in patients with coeliac disease on a glutenâ€free diet: beyond traditional metabolic factors. Alimentary Pharmacology and Therapeutics, 2018, 48, 538-546.	1.9	49
67	TRANS-TACE: Prognostic Role of the Transient Hypertransaminasemia after Conventional Chemoembolization for Hepatocellular Carcinoma. Journal of Personalized Medicine, 2021, 11, 1041.	1.1	48
68	The ART Score Is Not Effective to Select Patients for Transarterial Chemoembolization Retreatment in an Italian Series. Digestive Diseases, 2014, 32, 711-716.	0.8	47
69	Metronomic capecitabine as second-line treatment for hepatocellular carcinoma after sorafenib discontinuation. Journal of Cancer Research and Clinical Oncology, 2018, 144, 403-414.	1.2	45
70	Hand-foot skin reaction (HFSR) and overall survival (OS) in the phase 3 RESORCE trial of regorafenib for treatment of hepatocellular carcinoma (HCC) progressing on sorafenib.. Journal of Clinical Oncology, 2018, 36, 412-412.	0.8	40
71	Utility of Tumor Burden Score to Stratify Prognosis of Patients with Hepatocellular Cancer: Results of 4759 Cases from ITA.LI.CA Study Group. Journal of Gastrointestinal Surgery, 2018, 22, 859-871.	0.9	38
72	Incidence and Recurrence of Portal Vein Thrombosis in Cirrhotic Patients. Thrombosis and Haemostasis, 2019, 119, 496-499.	1.8	37

#	Article	IF	Citations
73	Assessing the impact of COVID-19 on liver cancer management (CERO-19). JHEP Reports, 2021, 3, 100260.	2.6	36
74	Diagnosis and Therapy of Autoimmune Hepatitis. Mini-Reviews in Medicinal Chemistry, 2009, 9, 847-860.	1.1	35
75	The importance of liver functional reserve in the non-surgical treatment of hepatocellular carcinoma. Journal of Hepatology, 2022, 76, 1185-1198.	1.8	35
76	Non-Alcoholic Steatohepatitis as a Risk Factor for Intrahepatic Cholangiocarcinoma and Its Prognostic Role. Cancers, 2020, 12, 3182.	1.7	34
77	Treatment of hepatocellular carcinoma in Child-Pugh B patients. Digestive and Liver Disease, 2013, 45, 852-858.	0.4	32
78	Clinical features and effect of antiviral therapy on anti-liver/kidney microsomal antibody type 1 positive chronic hepatitis C. Journal of Hepatology, 2009, 50, 1093-1101.	1.8	31
79	Real-Life Clinical Data of Cabozantinib for Unresectable Hepatocellular Carcinoma. Liver Cancer, 2021, 10, 370-379.	4.2	31
80	Systemic treatments for hepatocellular carcinoma: challenges and future perspectives. Hepatic Oncology, 2018, 5, HEP01.	4.2	30
81	Metronomic Capecitabine in Patients With Hepatocellular Carcinoma Unresponsive to or Ineligible for Sorafenib Treatment: Report of Two Cases. Hepatitis Monthly, 2013, 13, e11721.	0.1	29
82	LBA-03 Efficacy and safety of regorafenib versus placebo in patients with hepatocellular carcinoma (HCC) progressing on sorafenib: results of the international, randomized phase 3 RESORCE trial. Annals of Oncology, 2016, 27, ii140.	0.6	29
83	The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib. PLoS ONE, 2020, 15, e0232449.	1.1	29
84	Evidence of a Genetic Basis for the Different Geographic Occurrences of Liver/Kidney Microsomal Antibody Type 1 in Hepatitis C. Digestive Diseases and Sciences, 2007, 52, 179-184.	1.1	26
85	c-MET receptor tyrosine kinase as a molecular target in advanced hepatocellular carcinoma. Journal of Hepatocellular Carcinoma, 2015, 2, 29.	1.8	26
86	Restaging Patients With Hepatocellular Carcinoma Before Additional Treatment Decisions: A Multicenter Cohort Study. Hepatology, 2018, 68, 1232-1244.	3.6	26
87	Autoimmune enteropathy and rheumatoid arthritis: A new association in the field of autoimmunity. Digestive and Liver Disease, 2006, 38, 926-929.	0.4	25
88	Long term effects of gluten-free diet in non-celiac wheat sensitivity. Clinical Nutrition, 2019, 38, 357-363.	2.3	24
89	Antitransglutaminase Antibodies and Giardiasis. American Journal of Gastroenterology, 2004, 99, 2505-2506.	0.2	21
90	Hepatitis C and autoreactivity. Digestive and Liver Disease, 2007, 39, S22-S24.	0.4	21

#	Article	IF	Citations
91	Coronavirus disease associated immune thrombocytopenia: Causation or correlation?. Journal of Microbiology, Immunology and Infection, 2021, 54, 531-533.	1.5	20
92	The Western immunoblotting pattern of anti-mitochondrial antibodies is independent of the clinical expression of primary biliary cirrhosis. Digestive and Liver Disease, 2005, 37, 108-112.	0.4	19
93	Current topics in autoimmune hepatitis. Digestive and Liver Disease, 2010, 42, 757-764.	0.4	19
94	Cholangiocarcinoma in Cirrhosis: Value of Hepatocyte Specific Magnetic Resonance Imaging. Digestive Diseases, 2015, 33, 735-744.	0.8	19
95	Autoimmune liver disease 2007. Molecular Aspects of Medicine, 2008, 29, 96-102.	2.7	18
96	Pattern of macrovascular invasion in hepatocellular carcinoma. European Journal of Clinical Investigation, 2021, 51, e13542.	1.7	18
97	Antinuclear antibodies in COVID 19. Clinical and Translational Science, 2021, 14, 1627-1628.	1.5	18
98	Anti-saccharomyces cerevisiae antibodies (ASCA) in coeliac disease. Gut, 2006, 55, 296.	6.1	17
99	Radiologic criteria of response to systemic treatments for hepatocellular carcinoma. Hepatic Oncology, 2017, 4, 129-137.	4.2	16
100	Outcomes with sorafenib (SOR) followed by regorafenib (REG) or placebo (PBO) for hepatocellular carcinoma (HCC): Results of the international, randomized phase 3 RESORCE trial.. Journal of Clinical Oncology, 2017, 35, 344-344.	0.8	16
101	LKM1-Positive Type 2 Autoimmune Hepatitis Following Allogenic Hematopoietic Stem-Cell Transplantation. American Journal of Gastroenterology, 2008, 103, 1313-1314.	0.2	15
102	International and multicenter realâ€world study of sorafenibâ€treated patients with hepatocellular carcinoma under dialysis. Liver International, 2020, 40, 1467-1476.	1.9	15
103	Comparison of Prognostic Scores in Patients With Hepatocellular Carcinoma Treated With Sorafenib. Clinical and Translational Gastroenterology, 2021, 12, e00286.	1.3	15
104	Regorafenib Combined with Other Systemic Therapies: Exploring Promising Therapeutic Combinations in HCC. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 477-492.	1.8	15
105	Regorafenib for the treatment of hepatocellular carcinoma. Drugs of Today, 2018, 54, 1.	0.7	15
106	Clinical and serological profile of primary biliary cirrhosis in men. QJM - Monthly Journal of the Association of Physicians, 2007, 100, 534-535.	0.2	14
107	Multiple nuclear dots and rim-like/membranous IgG isotypes in primary biliary cirrhosis. Autoimmunity, 2009, 42, 224-227.	1.2	14
108	Limitation of the simplified scoring system for the diagnosis of autoimmune Hepatitis with acute onset. Liver International, 2021, 41, 529-534.	1.9	14

#	Article	IF	Citations
109	Contrast-Enhanced Ultrasound LI-RADS LR-5 in Hepatic Tuberculosis: Case Report and Literature Review of Imaging Features. Gastroenterology Insights, 2021, 12, 1-9.	0.7	13
110	Beneficial Prognostic Effects of Aspirin in Patients Receiving Sorafenib for Hepatocellular Carcinoma: A Tale of Multiple Confounders. Cancers, 2021, 13, 6376.	1.7	13
111	Acute Icteric Hepatitis Induced By a Short Course of Low-Dose Cyclophosphamide in a Patient with Lupus Nephritis. Digestive Diseases and Sciences, 2005, 50, 2364-2365.	1.1	12
112	Sensorineural Hearing Loss and Celiac Disease: A Coincidental Finding. Canadian Journal of Gastroenterology & Hepatology, 2009, 23, 531-535.	1.8	12
113	Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma. Targeted Oncology, 2020, 15, 773-785.	1.7	12
114	Hepatic steatosis in chronic hepatitis C: impact on response to anti-viral treatment with peg-interferon and ribavirin. Alimentary Pharmacology and Therapeutics, 2005, 22, 943-949.	1.9	11
115	Diagnostic role of anti-dsDNA antibodies: do not forget autoimmune hepatitis. Nature Reviews Rheumatology, 2021, 17, 244-244.	3.5	11
116	Celiac Disease Diagnosed through Screening Programs in At-Risk Adults Is Not Associated with Worse Adherence to the Gluten-Free Diet and Might Protect from Osteopenia/Osteoporosis. Nutrients, 2018, 10, 1940.	1.7	10
117	Metabolic disorders across hepatocellular carcinoma in Italy. Liver International, 2018, 38, 2028-2039.	1.9	10
118	Monofocal hepatocellular carcinoma: How much does size matter?. Liver International, 2021, 41, 396-407.	1.9	10
119	Clinical and serological profile of primary biliary cirrhosis in young and elderly patients. QJM - Monthly Journal of the Association of Physicians, 2008, 101, 505-506.	0.2	9
120	Editorial: gut microbiota profile in patients with autoimmune hepatitisâ€"a clue for adjunctive probiotic therapy?. Alimentary Pharmacology and Therapeutics, 2020, 52, 392-394.	1.9	9
121	Imaging-based diagnosis of benign lesions and pseudolesions in the cirrhotic liver. Magnetic Resonance Imaging, 2021, 75, 9-20.	1.0	9
122	Acute-on-chronic liver failure: A complex clinical entity in patients with autoimmune hepatitis. Journal of Hepatology, 2021, 75, 1503-1505.	1.8	9
123	Survival by pattern of tumor progression during prior sorafenib (SOR) treatment in patients with hepatocellular carcinoma (HCC) in the phase III RESORCE trial comparing second-line treatment with regorafenib (REG) or placebo.. Journal of Clinical Oncology, 2017, 35, 229-229.	0.8	9
124	Correlation between LDH levels and response to sorafenib in HCC patients: an analysis of the ITA.LI.CA database. International Journal of Biological Markers, 2015, 30, 65-72.	0.7	8
125	Autoantibodies to speckled protein family in primary biliary cholangitis. Allergy, Asthma and Clinical Immunology, 2021, 17, 35.	0.9	8
126	Anti-neutrophil cytoplasm antibodies (ANCA) in autoimmune diseases: A matter of laboratory technique and clinical setting. Autoimmunity Reviews, 2021, 20, 102787.	2.5	8

#	Article	IF	Citations
127	Antibodies to gangliosides in coeliac disease with neurological manifestations. Alimentary Pharmacology and Therapeutics, 2005, 21, 291-292.	1.9	7
128	Systemic Lupus Erythematosus. New England Journal of Medicine, 2008, 358, 2412-2413.	13.9	7
129	Efficacy, safety, and health-related quality of life (HRQoL) of regorafenib in patients with hepatocellular carcinoma (HCC) progressing on sorafenib: Results of the international, double-blind phase 3 RESORCE trial. Annals of Oncology, 2016, 27, vi564.	0.6	7
130	CEUS LI-RADS are effective in predicting the risk hepatocellular carcinoma of liver nodules. Digestive and Liver Disease, 2017, 49, e22.	0.4	7
131	Anti-ganglioside antibodies and celiac disease. Allergy, Asthma and Clinical Immunology, 2021, 17, 53.	0.9	7
132	Very Low Alcohol Consumption Is Associated with Lower Prevalence of Cirrhosis and Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease. Nutrients, 2022, 14, 2493.	1.7	7
133	DAAs for HCV and risk of hepatocellular carcinoma: current standpoint. The Lancet Gastroenterology and Hepatology, 2018, 3, 736-738.	3.7	6
134	Clinical outcomes with long-term sorafenib treatment of patients with hepatocellular carcinoma: a multicenter real-life study. Future Oncology, 2018, 14, 3049-3058.	1.1	6
135	Decompensated Cirrhosis as Presentation of LKM1/LC1 Positive Type 2 Autoimmune Hepatitis in Adulthood. A Rare Clinical Entity of Difficult Management. Gastroenterology Insights, 2021, 12, 67-75.	0.7	6
136	An update of treatments of hepatocellular carcinoma in patients refractory to sorafenib. Drugs of Today, 2018, 54, 615.	0.7	6
137	A case of leptospirosis simulating colon cancer with liver metastases. World Journal of Gastroenterology, 2004, 10, 2455.	1.4	6
138	Pattern of progression of intrahepatic cholangiocarcinoma: Implications for secondâ€line clinical trials. Liver International, 2022, 42, 458-467.	1.9	6
139	Segmental Distribution of Hepatocellular Carcinoma in Cirrhotic Livers. Diagnostics, 2022, 12, 834.	1.3	6
140	Immunoglobulin GM and KM Allotypes and Prevalence of Anti-LKM1 Autoantibodies in Patients with Hepatitis C Virus Infection. Journal of Virology, 2006, 80, 5097-5099.	1.5	5
141	Updated overall survival (OS) analysis from the international, phase 3, randomized, placebo-controlled RESORCE trial of regorafenib for patients with hepatocellular carcinoma (HCC) who progressed on sorafenib treatment. Annals of Oncology, 2017, 28, iii140.	0.6	5
142	Comparison of modified (m)RECISTand RECIST 1.1 assessments in the phase 3 RESORCE trial comparing regorafenib and placebo in patients with hepatocellular carcinoma who progressed during sorafenib treatment. Journal of Hepatology, 2017, 66, S451-S452.	1.8	5
143	Prognosis of Single Early-Stage Hepatocellular Carcinoma (HCC) with CEUS Inconclusive Imaging (LI-RADS LR-3 and LR-4) Is No Better than Typical HCC (LR-5). Cancers, 2022, 14, 336.	1.7	5
144	Antifilamentous Actin Antibodies by ELISA for the Diagnosis of Type 1 Autoimmune Hepatitis. American Journal of Gastroenterology, 2007, 102, 1131-1132.	0.2	4

#	Article	IF	Citations
145	999P Real-life clinical data of cabozantinib for unresectable hepatocellular carcinoma. Annals of Oncology, 2020, 31, S695.	0.6	4
146	Retrospective analysis of safety of ultrasound-guided percutaneous liver biopsy in the 21st century. European Journal of Gastroenterology and Hepatology, 2021, 33, e355-e362.	0.8	4
147	Tocilizumab: From Rheumatic Diseases to COVID-19. Current Pharmaceutical Design, 2021, 27, 1597-1607.	0.9	4
148	Surveillance for hepatocellular carcinoma with a 3-months interval in â€œextremely high-riskâ€•patients does not further improve survival. Digestive and Liver Disease, 2022, 54, 927-936.	0.4	4
149	Material deprivation affects the management and clinical outcome of hepatocellular carcinoma in a high-resource environment. European Journal of Cancer, 2021, 158, 133-143.	1.3	4
150	Hepatic Steatosis in Patients with Celiac Disease: The Role of Packaged Gluten-Free Foods. Nutrients, 2022, 14, 2942.	1.7	4
151	Surrogate Markers for Antimitochondrial Antibodyâ€“Negative Primary Biliary Cholangitis. American Journal of Gastroenterology, 2021, 116, 215-217.	0.2	3
152	MEDICAL TREATMENT OF HEPATOCELLULAR CARCINOMA. Mediterranean Journal of Hematology and Infectious Diseases, 2009, 1, e2009021.	0.5	3
153	Characteristics and survival of patients with primary biliary cholangitis and hepatocellular carcinoma. Digestive and Liver Disease, 2022, 54, 1215-1221.	0.4	3
154	Recalibrating survival prediction among patients receiving transâ€arterial chemoembolization for hepatocellular carcinoma. Liver Cancer International, 2021, 2, 45-53.	0.2	2
155	The duration of the conventional chemoembolization for hepatocellular carcinoma: factors affecting the procedural time. Hepatoma Research, 2022, 8, 27.	0.6	2
156	Paraneoplastic Anti-Tif1-gamma Autoantibody-positive Dermatomyositis as Clinical Presentation of Hepatocellular Carcinoma Recurrence. Journal of Clinical and Translational Hepatology, 2022, 000, 000-000.	0.7	2
157	Anti-neuronal antibodies in patients with celiac disease and neurological disorders. Gastroenterology, 2003, 124, A15.	0.6	1
158	861 A COMPLEX IMMUNOREGULATORY DEFICIENCY CHARACTERISES TYPE 1 AUTOIMMUNE HEPATITIS. Journal of Hepatology, 2008, 48, S323.	1.8	1
159	877 INCREASED REGULATORY POTENTIAL AND IMBALANCE OF THE VDELTA1/VDELTA2 RATIO IN PATIENTS WITH DIFFERENT MANIFESTATIONS OF HEPATITIS C. Journal of Hepatology, 2009, 50, S319.	1.8	1
160	489 CLINICAL IMPACT AND BEHAVIOUR OF SERUM AUTOANTIBODIES IN ADULT LIVER TRANSPLANTATION. Journal of Hepatology, 2010, 52, S197-S198.	1.8	1
161	Survival of patients with hepatocellular carcinoma (HCC) within the Bologna Liver Oncology Group: comparison with international guidelines. Digestive and Liver Disease, 2015, 47, e33.	0.4	1
162	CEUS LI-RADS are effective in predicting the risk hepatocellular carcinoma of liver nodules. Journal of Hepatology, 2017, 66, S208-S209.	1.8	1

#	Article	IF	Citations
163	SAT-484-CEUS pattern of hepatocellular carcinoma: Prognostic implication. Journal of Hepatology, 2019, 70, e846.	1.8	1
164	An update on atezolizumab for hepatocellular carcinoma. Drugs of Today, 2021, 57, 365.	0.7	1
165	Pattern of progression of intrahepatic cholangiocarcinoma impacts on survival: Implications for second-line trials. Digestive and Liver Disease, 2021, 53, S19.	0.4	1
166	A multicenter, observational, phase 4 study (STELLAR) to evaluate the safety and tolerability of lenvatinib (LEN) in patients with advanced or unresectable hepatocellular carcinoma (uHCC).. Journal of Clinical Oncology, 2022, 40, TPS485-TPS485.	0.8	1
167	Nailfold capillaroscopy in primary biliary cirrhosis: a useful tool for the early diagnosis of scleroderma. Journal of Gastrointestinal and Liver Diseases, 2014, 23, 39-43.	0.5	1
168	Risk of Drop-Out from Follow-Up Evaluations for Celiac Disease: Is It Similar for All Patients?. Nutrients, 2022, 14, 1223.	1.7	1
169	77 Coeliac diasease in atopy. Journal of Allergy and Clinical Immunology, 2000, 105, S27.	1.5	0
170	Diagnostic accuracy of anti-nuclear antibodies giving a multiple nuclear dots (MND) or a membranous (RL/M) pattern in primary biliary cirrhosis. Digestive and Liver Disease, 2006, 38, A75.	0.4	0
171	Natural course and incidence of non-organ specific autoantibodies (NOSA) and HCV infection in the general population: A nested case-control study of the dionysos cohort. Digestive and Liver Disease, 2006, 38, A78-A79.	0.4	0
172	Anti-extractable nuclear antigens (ENA) antibodies in primary biliary cirrhosis. Digestive and Liver Disease, 2006, 38, A80-A81.	0.4	0
173	[537] ANTI-LIVER KIDNEY MICROSOME TYPE ONE (ANTI-LKM1) POSITIVE HCV-RELATED CHRONIC LIVER DISEASE: PRESENTATION AND NATURAL HISTORY. Journal of Hepatology, 2007, 46, S204.	1.8	0
174	[664] DETECTION OF MND AND RL/M ANTI-NUCLEAR ANTIBODIES PATTERNS: A RELIABLE DIAGNOSTIC TOOL IN ANTI-MITOCHONDRIAL ANTIBODIES NEGATIVE PRIMARY BILIARY CIRRHOSISd. Journal of Hepatology, 2007, 46, S251-S252.	1.8	0
175	PO.8 COELIAC DISEASE MISDIAGNOSIS IN PATIENTS WITH COMMON VARIABLE IMMUNODEFICIENCY. Digestive and Liver Disease, 2008, 40, S173-S174.	0.4	0
176	665 PML NUCLEAR BODY COMPONENT SP140 IS A NOVEL AUTOANTIGEN IN PRIMARY BILIARY CIRRHOSIS. Journal of Hepatology, 2009, 50, S244.	1.8	0
177	1015 THE CHALLENGE OF TREATING HCC IN CHILD-PUGH B: NEED FOR SUBCLASSIFICATION. Journal of Hepatology, 2011, 54, S404.	1.8	0
178	OC-1 Prospective Italian multicenter field-practice study with sorafenib for advanced hepatocellular carcinoma. Digestive and Liver Disease, 2011, 43, S65.	0.4	0
179	OC-27 Diagnostic accuracy of different patterns of contrast enhanced ultrasound in characterization of new nodules in liver cirrhosis with and without history of previous hepatocellular carcinoma. Digestive and Liver Disease, 2011, 43, S73-S74.	0.4	0
180	T-17 Impact of Gadoxetic acid (Gd-EOB-DTPA)-enhanced MR on the non-invasive diagnosis of small hepatocellular carcinoma. Digestive and Liver Disease, 2011, 43, S82.	0.4	0

#	Article	IF	Citations
181	Coeliac disease: rational approach to the diagnosis. Italian Journal of Medicine, 2013, 1, 60.	0.2	0
182	Symptomatic onset identifies a more aggressive subset of primary biliary cirrhosis. Digestive and Liver Disease, 2014, 46, e5.	0.4	0
183	Stereotactic body radiotherapy for patients with hepatocellular carcinoma and intermediate grade cirrhosis â€“ Authors' reply. Lancet Oncology, The, 2017, 18, e193.	5.1	0
184	P.09.16 LONG-TERM SORAFENIB TREATMENT IN A LARGE COHORT OF HCC PATIENTS: A MULTICENTER STUDY. Digestive and Liver Disease, 2018, 50, e222.	0.4	0
185	4:12 PM Abstract No. 379 Updated overall survival (OS) analysis from the international, phase 3, randomized, placebo-controlled RESORCE trial of regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment. Journal of Vascular and Interventional Radiology, 2018, 29, S162-S163.	0.2	0
186	Prognostic scores for sorafenib-treated hepatocellular carcinoma patients: a validation study of the HAP and SAP scores. Journal of Hepatology, 2018, 68, S436-S437.	1.8	0
187	SAT-453-Effects of sorafenib on pancreatic volume and their clinical implications in patients with hepatocellular carcinoma. Journal of Hepatology, 2019, 70, e832.	1.8	0
188	FRI-462-A multicenter international study of sorafenib treatment in patients with hepatocellular carcinoma and chronic kidney disease undergoing hemodialysis. Journal of Hepatology, 2019, 70, e599-e600.	1.8	0
189	T02.02.8 CELIAC DISEASE: DO ALL PATIENTS ADHERE TO THE FOLLOW UP PROCEDURES IN THE SAME WAY?. Digestive and Liver Disease, 2020, 52, S87.	0.4	0
190	Natural history of hepatobiliary-hypointense only nodules found at magnetic resonance imaging with Gd-EOB-DTPA: time-dependent effects of dimensional increase and diffusion weighted imaging alterations. Journal of Hepatology, 2020, 73, S377.	1.8	0
191	Prognostication of hepatocellular carcinoma under sorafenib: external validation of the PROSASH-II model. Journal of Hepatology, 2020, 73, S394-S395.	1.8	0
192	Protective role of aspirin chronic assumption in patients treated with sorafenib for hepatocellular carcinoma. Journal of Hepatology, 2020, 73, S905.	1.8	0
193	Welcome to Gastroenterology Insights. Gastroenterology Insights, 2020, 11, 10-10.	0.7	0
194	Prognostication of hepatocellular carcinoma under sorafenib: external validation of the PROSASH-II model. Digestive and Liver Disease, 2020, 52, e15.	0.4	0
195	Real-life clinical data of cabozantinib for unresectable hepatocellular carcinoma: efficacy, safety and prognostic factors. Digestive and Liver Disease, 2021, 53, S10.	0.4	0
196	Identification of Regorafenib Prognostic Index (REP Index) via Recursive Partitioning Analysis in Patients with Advanced Hepatocellular Carcinoma Receiving Systemic Treatment: A Real-World Multi-Institutional Experience. Targeted Oncology, 2021, 16, 653-661.	1.7	0
197	Clinical predictors of response to sorafenib in patients with hepatocellular carcinoma.. Journal of Clinical Oncology, 2013, 31, e15149-e15149.	0.8	0
198	Survival by pattern of tumor progression during prior sorafenib (SOR) treatment in patients with hepatocellular carcinoma (HCC) in the phase III RESORCE trial comparing second-line treatment with regorafenib (REG) or placebo. , 2017, 55, .		0

#	Article	IF	Citations
199	Outcomes with sorafenib (SOR) followed by regorafenib (REG) or placebo (PBO) for hepatocellular carcinoma (HCC): Results of the international, randomized phase 3 RESORCE trial. , 2017, 55, .		0
200	Overall Survival (OS) Update: 2-year follow-up from the phase-3 RESORCE trial of Regorafenib for patients with hepatocellular carcinoma (HCC) progressing on Sorafenib. , 2019, 57, .		0
201	Steatosis in chronic hepatitis C. Gut, 2006, 55, 1047; author reply 1047-8.	6.1	0
202	Prognostic impact of sarcopenia on patients with advanced hepatocellular carcinoma treated with sorafenib. Digestive and Liver Disease, 2022, 54, S29.	0.4	0
203	The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib. , 2020, 15, e0232449.		0
204	The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib. , 2020, 15, e0232449.		0
205	The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib. , 2020, 15, e0232449.		0
206	The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib. , 2020, 15, e0232449.		0
207	T.08.10 IMPACT OF SARCOPENIA ON SURVIVAL OF PATIENTS AFFECTED BY ADVANCED HEPATOCELLULAR CARCINOMA TREATED WITH SORAFENIB. Digestive and Liver Disease, 2022, 54, S151.	0.4	0